CR2

Across TCGA pan-cancer cohorts, CR2 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated CR2 data layer compared with 17 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CR2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CR2 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

STAD, BLCA, and LUAD are the cancer types where CR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	1.000	0.331	.012	20	view →
BLCA	OS	Median	All	0.069	0.688	<.001	18	view →
LUAD	DFS	Median	II,III,IV	0.181	0.659	<.001	14	view →
BRCA	OS	Median	II,III,IV	0.706	0.913	.007	12	view →
LIHC	DFS	Median	All	0.266	0.562	.002	12	view →
LUSC	DFS	Median	II,III,IV	0.461	0.722	.005	8	view →
UCEC	DFS	Median	II,III,IV	0.875	0.434	.030	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	All	0.868	0.705	.005	4	view →
LGG	OS	Median	All	0.159	0.521	.010	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

CR2–STAD (DFS)

Open the STAD breakdown →